Discussion on the price of generic drugs of Seputinib (Serpatinib) in India

Selpercatinib (Selpercatinib), this targeted therapy for RET fusion-positive tumors, has brought new hope to many patients around the world. Abnormalities in the RET gene are closely related to the occurrence and development of various tumors, and Serpatinib can accurately inhibit the excessive activation of RET protein, thereby curbing the proliferation of cancer cells.

Although serpatinib has been launched in China, the high price - about more than 10,000 yuan per box - still prohibits many patients. At the same time, the price of original drugs abroad is even more prohibitive. Fortunately, in some countries such as Laos and Bangladesh, more reasonably priced generic drugs have emerged. The price is about more than 4,000 yuan, and the efficacy is similar to the original drug. But unfortunately, we have not yet seen regular generics of Serpatinib (Serpatinib) in the Indian market.

The efficacy of serpatinib has been demonstrated in a variety of cancers. Especially in non-small cell lung cancer (NSCLC), for those patients who carry RET gene fusion mutations, Serpatinib (Serpatinib) has shown a significant therapeutic effect, providing a powerful weapon to control the disease. In addition, in rare but highly malignant cancers such as medullary thyroid carcinoma (MTC), Serpatinib also provides a new treatment option for patients with RET gene mutations.

The emergence of serpatinib undoubtedly represents an important milestone in personalized cancer treatment. Compared with traditional chemotherapy, it is more targeted and can attack cancer cells more accurately, reducing damage to healthy cells, thus improving the treatment effect. With the continuous development of personalized treatment strategies, we have reason to believe that the survival rate and quality of life of cancer patients will be further improved.